Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/43934
Title: IDH1 mutation detection by droplet digital PCR in glioma
Authors: Wang, J
Zhao, Y
Li, J
Guo, C
Chen, F
Su, H
Zhao, H
Long, Y
Shao, J
To, ST 
Chen, Z
Keywords: Droplet digital PCR (ddPCR)
Glioma
Isocitrate dehydrogenase (IDH)
Quantitative real-time PCR (qRT-PCR)
Sensitivity
Issue Date: 2015
Publisher: Impact Journals LLC
Source: Oncotarget, 2015, v. 6, no. 37, p. 39651-39660 How to cite?
Journal: Oncotarget 
Abstract: Glioma is the most frequent central nervous system tumor in adults. The overall survival of glioma patients is disappointing, mostly due to the poor prognosis of glioblastoma (Grade IV glioma). Isocitrate dehydrogenase (IDH) is a key factor in metabolism and catalyzes the oxidative decarboxylation of isocitrate. Mutations in IDH genes are observed in over 70% of low-grade gliomas and some cases of glioblastoma. As the most frequent mutation, IDH1(R132H) has been served as a predictive marker of glioma patients. The recently developed droplet digital PCR (ddPCR) technique generates a large amount of nanoliter-sized droplets, each of which carries out a PCR reaction on one template. Therefore, ddPCR provides high precision and absolute quantification of the nucleic acid target, with wide applications for both research and clinical diagnosis. In the current study, we collected 62 glioma tissue samples (Grade II to IV) and detected IDH1 mutations by Sanger direct sequencing, ddPCR, and quantitative real-time PCR (qRT-PCR). With the results from Sanger direct sequencing as the standard, the characteristics of ddPCR were compared with qRTPCR. The data indicated that ddPCR was much more sensitive and much easier to interpret than qRT-PCR. Thus, we demonstrated that ddPCR is a reliable and sensitive method for screening the IDH mutation. Therefore, ddPCR is able to applied clinically in predicting patient prognosis and selecting effective therapeutic strategies. Our data also supported that the prognosis of Grade II and III glioma was better in patients with an IDH mutation than in those without mutation.
URI: http://hdl.handle.net/10397/43934
ISSN: 1949-2553
DOI: 10.18632/oncotarget.5630
Appears in Collections:Journal/Magazine Article

Access
View full-text via PolyU eLinks SFX Query
Show full item record

SCOPUSTM   
Citations

7
Last Week
0
Last month
Citations as of Nov 7, 2018

WEB OF SCIENCETM
Citations

6
Last Week
1
Last month
Citations as of Nov 9, 2018

Page view(s)

73
Last Week
0
Last month
Citations as of Nov 12, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.